Make better investment decisions with Simply Wall St's easy, visual tools that give you a competitive edge.
Zealand Pharma stock has delivered a strong 90.3% return over the past five years, yet its low overall value score and current market multiples suggest the shares may now be closer to fairly priced than a clear bargain.
-
Over five years, Zealand Pharma has returned 90.3%, which puts current buyers in a different position to those who entered earlier in the story.
-
The recent $100 million royalty deal with Royalty Pharma can support funding for rusfertide and other priorities. Reliance on successful product approvals and commercialization remains a key risk for how much value that capital ultimately creates.
-
With the company screening as attractive on only 2 of 6 valuation checks , Zealand Pharma does not stand out as obviously cheap on the broader metrics.
The stock's next move may depend on whether the current price already reflects the long term potential that recent deals and the pipeline aim to deliver.
Find out why Zealand Pharma's -3.5% return over the last year is lagging behind its peers.
Where Does Zealand Pharma Sit on Earnings?
The P/E ratio is a useful way to sanity check where Zealand Pharma trades against the earnings it is currently generating. For a biotech that already reports positive earnings, this gives you a clearer anchor than revenue alone.
Zealand Pharma trades on a P/E of about 3.6x, which sits far below both the broader biotech industry average of roughly 26.9x and the peer group average of about 15.2x. A fair P/E for the company, based on its size, business mix and risk profile, is estimated at around 3.5x. That leaves the current multiple only slightly above this tailored fair level.
Despite the recent $100 million royalty deal with Royalty Pharma drawing attention to the story, the P/E still sits close to what the model suggests is warranted for Zealand Pharma. The market is not pricing it like a high premium story on this metric, but it is also not heavily discounting the earnings stream.
Overall, Zealand Pharma looks priced at roughly a fair level on its P/E multiple.
See what the numbers say about this price — find out in our valuation breakdown.
The Zealand Pharma Narrative: What Would Justify Today's Price?
Simply Wall St Narratives pick up where the Zealand Pharma valuation puzzle leaves off by spelling out which future paths for growth, margins and earnings would need to play out for the stock to be worth meaningfully more or less than today's price, based on discussions on the Community page. Each Narrative presents Zealand Pharma's implied fair value as a thesis about the business that can be tracked over time, rather than a single static number.
Community views on Zealand Pharma are pulled in opposite directions, with one camp focused on obesity upside and another worried about execution and timing risk.
Bull case: 28% undervalued
"The alliance with Roche for petrelintide significantly derisks commercialization and broadens access to manufacturing and distribution scale, positioning Zealand to capitalize on the global surge in obesity and metabolic disorder prevalence..."
Read the full Bull Case to see why Zealand Pharma could be undervalued
Bear case: 10% overvalued
"The rapid expansion and technological arms race in obesity pharmacotherapy risks making petrelintide look second tier by the time it launches, if competitors deliver higher efficacy or more convenient regimens..."
Read the full Bear Case to see why Zealand Pharma could be overvalued
Do you think there's more to the story for Zealand Pharma? Head over to our Community to see what others are saying!
The Bottom Line
Zealand Pharma now looks priced at about the right level on its main market multiples, with the current P/E sitting close to the tailored fair ratio estimate. The broader valuation checks are still weak though, which suggests the stock does not clearly stand out as a bargain based on the wider set of metrics. From here, the real swing factor is whether the pipeline and partnerships convert into earnings that justify a stronger re rating, or whether execution and timing risks keep the valuation closer to where it is today.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Companies discussed in this article include ZEAL.CO .
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com
